Acute Ischemic Stroke Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast 2023-2027

Published: Oct 2022 Pages: 168 SKU: IRTNTR45749

Acute Ischemic Stroke Therapeutics Market Forecast 2023-2027

The acute ischemic stroke (AIS) therapeutics market is estimated to increase by USD 1,524.49 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 5.72%. The growth of the market depends on several factors, including the rising prevalence of disease, the increasing adoption of NOACs, and the increasing prevalence of sedentary lifestyles. 

 What will the Size of the Acute Ischemic Stroke Therapeutics Market be During the Forecast Period?

To learn more about this report, Download Report Sample

Market: Key Drivers, Trends, Challenges, and Customer Landscape

The high-risk factors, such as obesity, atherosclerosis, hypertension, and old age are notably driving the market growth, although factors such as unmet needs for anticoagulant reversal agents may impede the market growth.

Key Driver

High-risk factors, such as obesity, atherosclerosis, hypertension, and old age are notably driving the acute ischemic stroke (AIS) therapeutics market growth. Cardiovascular diseases, particularly MI (myocardial infarction) and stroke are the leading causes of disability and death globally and are a major public health concern. AIS is the most common form of stroke that occurs when oxygen-rich blood supply to a part of the brain is blocked either by the formation of plaque or a blood clot. If not treated on time, a stroke can result in disability or even death. Therefore, quick and acute treatment with generic drugs such as alteplase is recommended within 3-4 hours after the onset of the first symptom of a stroke.

As per the Centers for Disease Control and Prevention (CDC), ischemic stroke accounts for approximately 87% of all strokes. Stroke is the second-leading cause of death globally. An ischemic stroke occurs when an artery carrying oxygen-rich blood to the brain is blocked by a blood clot. A transient ischemic attack is also a type of ischemic stroke and lasts for a short time of fewer than five minutes. This mini-stroke occurs when blood flow to the brain is blocked for a shorter duration. A transient ischemic attack (TIA) is generally a warning sign of a stroke in the future. One-third of people, who had an untreated transient ischemic attack, suffered a major stroke within a year. According to the World Stroke Organization, currently, 15-16 million people suffer from stroke globally, while 5.8-6 million people die from it. High-risk factors, such as obesity, atherosclerosis, hypertension, and old age, are the major contributors to the growth of the segment during the forecast period.

Key Trend

TBI, a value-addition in AIS research is the primary trend driving the market growth. AIS is a complex cardiac disease that requires the integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches called translational bioinformatics (TBI) that can integrate and analyze these heterogeneous features are being developed to enhance the clinical guidelines for treating and preventing AIS. TBI is a computational technology that focuses on integrating and analyzing data obtained from bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source that not only enables data integration but also improves data representation by using tools such as Ontologies and Controlled vocabulary. These vocabulary tools provide a standard way for data representation, in which the data is accepted by specific user communities, such as Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).

In AIS, the data element that requires integration refers to the presence or absence of a risk gene (HDAC9, PITX2, ZFHX3, NINJ2, PRKCH, and 9p21) in the genome of each patient (called genotypic data) with that of the clinical element, which is extracted from clinical tests (such as magnetic resonance imaging) of each patient, on which the physician relies. The compilation of all these details from each patient provides doctors with knowledge about the clinical scenario of each patient and a better approach to treatment.

Key Challenge

Unmet needs for anticoagulant reversal agents may impede the market growth. Though anticoagulants play an important role in treating AIS, they are sometimes associated with side effects such as excessive bleeding. The side effects can be reversed using reversal agents, which are referred to as antidotes for anticoagulants. The antidotes available in the market include vitamin K, protamine, and prothrombin complex concentrates, which reverse the action of warfarin and heparin. Though NOACs (novel oral anticoagulants) show better safety and efficacy profiles, the acceptability of these drugs is low due to the unavailability of antidotes in the market.

The limited availability of anticoagulant reversal agents in the market will limit the uptake of novel anticoagulants in the market. Recently, the reversal agent, idarucizumab, which acts as the antidote to dabigatran, was approved by the US FDA. Newer anticoagulants, such as direct thrombin inhibitors or Factor Xa inhibitors, do not have any specific reversal agents. Research is still underway for the development of reversal agents. Thus, the unmet need existing in the market for anticoagulant reversal agents limits the use of anticoagulants, thereby negatively affecting the market growth.

Key Market Customer Landscape

Our analysis of the Life Cycle of the Global AIS therapeutics market indicates a movement from the innovator’s stage to the laggard’s stage. The report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries, including the US, Canada, the UK, Germany, and China. Technavio has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies from 2022 to 2027.

Global Market Customer Landscape

Who are the Major Acute Ischemic Stroke Therapeutics Market Players?                                     

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market 

Pfizer Inc- Under the unified segment, the company is engaged in the discovery, and development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide. The company's key offerings include acute ischemic stroke therapeutics such as Plavix.

We also have detailed analyses of the market’s competitive landscape and offer information on 20 market companies, including :

  • Athersys Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Medtronic Plc
  • NoNO Inc.
  • SanBio Co Ltd.
  • Stryker Corp.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak. 

What is the Fastest-Growing Segment in the Market?

The market share growth by the thrombolytics segment will be significant during the forecast period. The high market share of this segment is attributed to the availability of the US FDA-approved AIS therapeutic, IV alteplase, for the treatment of AIS in 1987. The drug, sold under the brand name Activase, is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). IV (intravenous) administration of Activase remains the mainstay treatment for AIS. Activase produces improved neurological outcomes in a large number of AIS patients, which results in a high adoption rate among general physicians and patients, thus, bolstering market growth.

Get a glance at the market contribution of various segments Request a PDF Sample

The thrombolytics segment showed a gradual increase in market share, from USD 2,464.99 million in 2017 and continued to grow by 2021. As per the NIH, the therapeutic efficacy of alteplase, administered within 3-4 hours after the onset of initial symptoms of AIS, is 52.4% when compared with 45.2% for a similarly administered placebo. The extended time window for the administration of alteplase further increases the prescription value of thrombolytic drugs, thus driving the market growth. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.

Which are the Key Regions for Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 38% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The expected approval of late-stage pipeline molecules, such as BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem, and NA-1, is also expected to boost market growth during the forecast period. North America is one of the most developed regions in the world. The market in the region, therefore, witnesses the availability of various diagnostics and drugs for the treatment of stroke. Despite the increasing use of stroke therapeutics in this region, the market faces a tough challenge from alternative treatment options.

Segment Overview

Our report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by type, distribution channel, and region.

  • Type Outlook (USD Million, 2017 - 2027)
    • Thrombolytics
    • Anticoagulants
    • Antiplatelets
    • Antihypertensives
  • Distribution Channel Outlook (USD Million, 2017 - 2027)
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Argentina
      • Brazil

Market Analyst Overview

The Market encompasses treatments for one of the leading causes of disability and mortality worldwide. With a focus on tissue plasminogen activators (TPA), anticoagulants, and antiplatelets, healthcare providers aim to mitigate the impact of ischemic strokes. Hospitals and clinics are primary end users, particularly in regions like North America, Europe, and Asia-Pacific. Factors such as high blood pressure, cholesterol, and diabetes drive the demand for stroke therapeutics. Major players like Bristol-Myers Squibb Company and Johnson & Johnson Inc. dominate the market, with research institutions like Osaka Metropolitan University contributing to innovation. Despite pricing pressures and patent expiries, advancements in recombinant technology and robotic therapy offer hope for improving outcomes in stroke recovery.

Acute Ischemic Stroke Therapeutics Market Scope

Report Coverage

Details

Page number

168

Base year

2022

Historical year

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.72%

Market growth 2023-2027

USD 1,524.49 million

Market structure

Fragmented

YoY growth (%)

5.49

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, UK, Germany, and China

Competitive landscape

Leading companies, Competitive Strategies, Consumer engagement scope

Key companies profiled

Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Medtronic Plc, NoNO Inc., SanBio Co Ltd., Stryker Corp., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 18: Five forces analysis - Comparison between 2022 and 2027
    • 4.2 Bargaining power of buyers
      • Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 4.3 Bargaining power of suppliers
      • Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 4.4 Threat of new entrants
      • Exhibit 21: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 4.5 Threat of substitutes
      • Exhibit 22: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 4.6 Threat of rivalry
      • Exhibit 23: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 4.7 Market condition
      • Exhibit 24: Chart on Market condition - Five forces 2022 and 2027

    5 Market Segmentation by Type

    • 5.1 Market segments
      • Exhibit 25: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 26: Data Table on Type - Market share 2022-2027 (%)
    • 5.2 Comparison by Type
      • Exhibit 27: Chart on Comparison by Type
      • Exhibit 28: Data Table on Comparison by Type
    • 5.3 Thrombolytics - Market size and forecast 2022-2027
      • Exhibit 29: Chart on Thrombolytics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 30: Data Table on Thrombolytics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 31: Chart on Thrombolytics - Year-over-year growth 2022-2027 (%)
      • Exhibit 32: Data Table on Thrombolytics - Year-over-year growth 2022-2027 (%)
    • 5.4 Anticoagulants - Market size and forecast 2022-2027
      • Exhibit 33: Chart on Anticoagulants - Market size and forecast 2022-2027 ($ million)
      • Exhibit 34: Data Table on Anticoagulants - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Chart on Anticoagulants - Year-over-year growth 2022-2027 (%)
      • Exhibit 36: Data Table on Anticoagulants - Year-over-year growth 2022-2027 (%)
    • 5.5 Antiplatelets - Market size and forecast 2022-2027
      • Exhibit 37: Chart on Antiplatelets - Market size and forecast 2022-2027 ($ million)
      • Exhibit 38: Data Table on Antiplatelets - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Chart on Antiplatelets - Year-over-year growth 2022-2027 (%)
      • Exhibit 40: Data Table on Antiplatelets - Year-over-year growth 2022-2027 (%)
    • 5.6 Antihypertensives - Market size and forecast 2022-2027
      • Exhibit 41: Chart on Antihypertensives - Market size and forecast 2022-2027 ($ million)
      • Exhibit 42: Data Table on Antihypertensives - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Chart on Antihypertensives - Year-over-year growth 2022-2027 (%)
      • Exhibit 44: Data Table on Antihypertensives - Year-over-year growth 2022-2027 (%)
    • 5.7 Other therapeutics - Market size and forecast 2022-2027
      • Exhibit 45: Chart on Other therapeutics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 46: Data Table on Other therapeutics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Chart on Other therapeutics - Year-over-year growth 2022-2027 (%)
      • Exhibit 48: Data Table on Other therapeutics - Year-over-year growth 2022-2027 (%)
    • 5.8 Market opportunity by Type
      • Exhibit 49: Market opportunity by Type ($ million)

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 50: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 51: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 52: Chart on Comparison by Distribution Channel
      • Exhibit 53: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacies - Market size and forecast 2022-2027
      • Exhibit 54: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 55: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 57: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
    • 6.4 Retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 58: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 59: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 61: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 6.5 Online pharmacies - Market size and forecast 2022-2027
      • Exhibit 62: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 63: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 65: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 66: Market opportunity by Distribution Channel ($ million)

    7 Customer Landscape

    • 7.1 Customer landscape overview
      • Exhibit 67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    8 Geographic Landscape

    • 8.1 Geographic segmentation
      • Exhibit 68: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 69: Data Table on Market share by geography 2022-2027 (%)
    • 8.2 Geographic comparison
      • Exhibit 70: Chart on Geographic comparison
      • Exhibit 71: Data Table on Geographic comparison
    • 8.3 North America - Market size and forecast 2022-2027
      • Exhibit 72: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 75: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 8.4 Europe - Market size and forecast 2022-2027
      • Exhibit 76: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 79: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 8.5 Asia - Market size and forecast 2022-2027
      • Exhibit 80: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 83: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 8.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 84: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 87: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 8.7 US - Market size and forecast 2022-2027
      • Exhibit 88: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 91: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 8.8 UK - Market size and forecast 2022-2027
      • Exhibit 92: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 95: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 8.9 Germany - Market size and forecast 2022-2027
      • Exhibit 96: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 99: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 8.10 China - Market size and forecast 2022-2027
      • Exhibit 100: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 103: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 8.11 Canada - Market size and forecast 2022-2027
      • Exhibit 104: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 107: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 8.12 Market opportunity by geography
      • Exhibit 108: Market opportunity by geography ($ million)

    9 Drivers, Challenges, and Trends

    • 9.1 Market drivers
      • 9.2 Market challenges
        • 9.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 9.4 Market trends

          10 Vendor Landscape

          • 10.1 Overview
            • 10.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 10.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 10.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            11 Vendor Analysis

            • 11.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 11.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 11.3 Amgen Inc.
              • Exhibit 115: Amgen Inc. - Overview
              • Exhibit 116: Amgen Inc. - Product / Service
              • Exhibit 117: Amgen Inc. - Key offerings
            • 11.4 AstraZeneca Plc
              • Exhibit 118: AstraZeneca Plc - Overview
              • Exhibit 119: AstraZeneca Plc - Product / Service
              • Exhibit 120: AstraZeneca Plc - Key news
              • Exhibit 121: AstraZeneca Plc - Key offerings
            • 11.5 Athersys Inc.
              • Exhibit 122: Athersys Inc. - Overview
              • Exhibit 123: Athersys Inc. - Product / Service
              • Exhibit 124: Athersys Inc. - Key offerings
            • 11.6 Bayer AG
              • Exhibit 125: Bayer AG - Overview
              • Exhibit 126: Bayer AG - Business segments
              • Exhibit 127: Bayer AG - Key offerings
              • Exhibit 128: Bayer AG - Segment focus
            • 11.7 Biogen Inc.
              • Exhibit 129: Biogen Inc. - Overview
              • Exhibit 130: Biogen Inc. - Product / Service
              • Exhibit 131: Biogen Inc. - Key offerings
            • 11.8 Boehringer Ingelheim International GmbH
              • Exhibit 132: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 133: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 134: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 135: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 136: Boehringer Ingelheim International GmbH - Segment focus
            • 11.9 Bristol Myers Squibb Co.
              • Exhibit 137: Bristol Myers Squibb Co. - Overview
              • Exhibit 138: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 139: Bristol Myers Squibb Co. - Key offerings
            • 11.10 Daiichi Sankyo Co. Ltd.
              • Exhibit 140: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 141: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 142: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 143: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 144: Daiichi Sankyo Co. Ltd. - Segment focus
            • 11.11 F. Hoffmann La Roche Ltd.
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
            • 11.12 Johnson and Johnson
              • Exhibit 150: Johnson and Johnson - Overview
              • Exhibit 151: Johnson and Johnson - Business segments
              • Exhibit 152: Johnson and Johnson - Key news
              • Exhibit 153: Johnson and Johnson - Key offerings
              • Exhibit 154: Johnson and Johnson - Segment focus
            • 11.13 Medtronic Plc
              • Exhibit 155: Medtronic Plc - Overview
              • Exhibit 156: Medtronic Plc - Business segments
              • Exhibit 157: Medtronic Plc - Key news
              • Exhibit 158: Medtronic Plc - Key offerings
              • Exhibit 159: Medtronic Plc - Segment focus
            • 11.14 Merck and Co. Inc.
              • Exhibit 160: Merck and Co. Inc. - Overview
              • Exhibit 161: Merck and Co. Inc. - Business segments
              • Exhibit 162: Merck and Co. Inc. - Key news
              • Exhibit 163: Merck and Co. Inc. - Key offerings
              • Exhibit 164: Merck and Co. Inc. - Segment focus
            • 11.15 Pfizer Inc.
              • Exhibit 165: Pfizer Inc. - Overview
              • Exhibit 166: Pfizer Inc. - Product / Service
              • Exhibit 167: Pfizer Inc. - Key news
              • Exhibit 168: Pfizer Inc. - Key offerings
            • 11.16 Sanofi SA
              • Exhibit 169: Sanofi SA - Overview
              • Exhibit 170: Sanofi SA - Business segments
              • Exhibit 171: Sanofi SA - Key news
              • Exhibit 172: Sanofi SA - Key offerings
              • Exhibit 173: Sanofi SA - Segment focus
            • 11.17 Teva Pharmaceutical Industries Ltd.
              • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 177: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 178: Teva Pharmaceutical Industries Ltd. - Segment focus

            12 Appendix

            • 12.1 Scope of the report
              • 12.2 Inclusions and exclusions checklist
                • Exhibit 179: Inclusions checklist
                • Exhibit 180: Exclusions checklist
              • 12.3 Currency conversion rates for US$
                • Exhibit 181: Currency conversion rates for US$
              • 12.4 Research methodology
                • Exhibit 182: Research methodology
                • Exhibit 183: Validation techniques employed for market sizing
                • Exhibit 184: Information sources
              • 12.5 List of abbreviations
                • Exhibit 185: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              acute ischemic stroke therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis